Keith T. Flaherty, AACR President, Director of clinical cancer research, Mass General Cancer Center, professor at Harvard Medical School, shared AACR’s post on X, adding:
“AACR lymphoma 2026 integrated discoveries in epigenetics, disease modeling, and computational biology with advances in antibody evolution, next-generation clinical assessment, degraders, and cellular therapies.
We thank the participants for convening to improve patient outcomes.”
Quoting AACR’s post:
“AACR lymphoma 2026 chair Michael R. Green adjourned the AACR Conference on Advances in Malignant Lymphoma.
We thank the cochairs, invited speakers, and abstract presenters for their contributions to this outstanding program.”
Other articles featuring Keith T. Flaherty and AACR on OncoDaily.